Enliven Therapeutics, Inc.
ELVN
$20.63
$0.311.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -100.22M | -94.83M | -89.02M | -85.21M | -82.83M |
| Total Depreciation and Amortization | 315.00K | 312.00K | 317.00K | 315.00K | 313.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.03M | 22.96M | 20.06M | 15.00M | 10.75M |
| Change in Net Operating Assets | 2.30M | -2.40M | -4.54M | 1.43M | -403.00K |
| Cash from Operations | -70.58M | -73.96M | -73.19M | -68.47M | -72.17M |
| Capital Expenditure | -181.00K | -44.00K | -44.00K | -58.00K | -52.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -166.43M | -16.64M | -35.95M | 2.02M | -48.36M |
| Cash from Investing | -166.61M | -16.69M | -36.00M | 1.96M | -48.41M |
| Total Debt Issued | -- | -- | -- | -- | -161.37M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 259.70M | 43.13M | 133.17M | 93.28M | 253.56M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | -453.00K |
| Cash from Financing | 259.70M | 43.13M | 133.17M | 93.28M | 91.74M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.51M | -47.51M | 23.98M | 26.77M | -28.84M |